Monolaurin, from coconut and breast milk, damages the outer coats of some bacteria, viruses, and fungi and quiets staph toxins in laboratory tests. Human proof is thin, mostly test-tube and animal work with limited skin use. It appears safe, inexpensive, and low-risk, but broad immune-boosting claims are unproven and whether swallowed doses survive digestion is unresolved. (Full Review)

Protocol

Dose

750 mg–3 g

Pure monolaurin pellets (Lauricidin), 1–3× daily; maintenance ~3 g twice daily

Titration

Start low, go slow

Begin ~750 mg once daily, increase every few days

Timing

With meals, divided

Split doses through the day, taken with fat-containing food

Time to effect

Topical (skin)

Weeks

Effect on skin colonization seen over weeks in limited human data

Oral

Not established

No validated onset window; any benefit is subjective

Benefits

Low: Topical antibacterial activity against gram-positive bacteria; suppression of bacterial toxin production and biofilm formation

Speculative: Antiviral activity against enveloped viruses; antifungal activity against Candida; immune and mucosal anti-inflammatory modulation; general immune support and cold or flu prevention

Contraindications

Pregnancy or breastfeeding

Significant immunocompromise or immunosuppressive therapy

Known coconut allergy

Key Interactions

Immunosuppressants (ciclosporin, tacrolimus, systemic corticosteroids)

Beta-lactam antibiotics (methicillin, oxacillin, amoxicillin)

Overlapping antimicrobial supplements (caprylic acid, oregano oil, olive leaf extract, berberine, NAC)

Risk & Side Effects

Low: Gastrointestinal disturbance

Speculative: Herxheimer-type die-off reaction; theoretical suppression of adaptive immune responses; coconut-related allergic reactions; unknown long-term and pregnancy safety

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation an antimicrobial or anti-inflammatory effect might lower
CBC with differential	Lymphocytes ~1.5–3.0 × 10⁹/L	Screens immune-cell counts given the theoretical immune-suppression concern
Fasting lipid panel	LDL-C < 100 mg/dL; HDL-C > 50 mg/dL	Monitors any lipid shift, since monolaurin derives from lauric acid
Staphylococcal skin/nasal swab culture	Negative or reduced colonization	Objective measure when the goal is reducing S. aureus carriage

Cadence: Baseline before starting, then roughly every 3–6 months if used long-term

Qualitative Assessment

Frequency and duration of minor infections (colds, skin flare-ups)
Digestive comfort and stool regularity
Energy levels and general sense of wellness
Skin condition where topical use is the goal

Monolaurin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment